An observational study in Hypoparathyroidism and Pseudo Hypoparathyroidism, sponsored by Dacima Consulting. Not yet recruiting at 1 site in Tunisia. Per ClinicalTrials.gov, last updated 2025-02-21.
Sponsored by Dacima Consulting · Observational
Observational, multicenter, national, cross-sectional study aiming to describe the epidemiological clinical, biological and therapeutic profile of patients suffering from defect in secretion (hypoparathyroidism) or action (pseudo-hypoparathyroidism) of parathyroid hormone.
Endocrinologists from both sectors (public and private) are participating in the study. Data will be captured electronically by DACIMA Clinical Suite, according to FDA 21 CFR part 11 (Food and Drug Administration 21 Code of Federal Regulations part 11), HIPAA (Health Insurance Portability and Accountability Act) \& ICH (International Conference on Harmonisation) requirements.
128 studies on the registry are indexed under Hypoparathyroidism; 30 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 147 across 48 observational studies indexed under Hypoparathyroidism.
Browse Hypoparathyroidism studies →Dacima Consulting is the lead sponsor of 18 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Consecutive patients suffering from hypoparathyroidism and/or pseudo hypoparathyroidism
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Incidence of primary hypoparathyroidism
Number of subjects with primary hypoparathyroidism at enrollment
Time frame: Day 1
Incidence of congenital hypoparathyroidism
Number of subjects with congenital hypoparathyroidism at enrollment
Time frame: Day 1
Incidence of acquired hypoparathyroidism
Number of subjects with acquired hypoparathyroidism at enrollment
Time frame: Day 1
Incidence of secondary hypoparathyroidism
Number of subjects with secondary hypoparathyroidism at enrollment
Time frame: Day 1
Plan to share: Undecided
Start is estimated for Feb 2025; primary completion for Jul 2025, 5 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dacima Consulting